asal naloxone and flumazenil effects on cigarette and cannabis craving and abstinence
Phase 1
Recruiting
- Conditions
- Tobacco use disorderCannabis use disorder
- Registration Number
- ACTRN12617000325303
- Lead Sponsor
- Go Medical Industries Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do nasal naloxone and flumazenil modulate opioid and GABA-A receptor pathways in tobacco and cannabis use disorders?
What is the comparative efficacy of nasal naloxone/flumazenil versus standard-of-care treatments for tobacco and cannabis use disorders?
Which biomarkers correlate with reduced craving or abstinence success in ACTRN12617000325303's pilot study on nasal naloxone and flumazenil?
What are the safety profiles and adverse event management strategies for nasal naloxone and flumazenil in substance use disorder trials?
How does Go Medical's nasal naloxone/flumazenil compare to other opioid and benzodiazepine antagonists in treating tobacco and cannabis use disorders?